Elisa Giorgio

Elisa Giorgio

Auto-generated profile, based on publicly available information

Elisa Giorgio

Department of Molecular Medicine, University of Pavia, Italy

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2015 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
EGElisa Giorgio
Elisa Giorgio
DRDaniel Robyr
Daniel Robyr
MSMalte Spielmann
Malte Spielmann
EFEnza Ferrero
Enza Ferrero
EGEleonora Di Gregorio
Eleonora Di Gregorio
ABAlfredo Brusco
Alfredo Brusco
Chromosomal rearrangements with duplication of the lamin B1 (LMNB1) gene underlie autosomal dominant adult-onset demyelinating leukodystrophy (ADLD), a rare neurological disorder in which overexpression of LMNB1 causes progressive central nervous system demyelination. However, we previously reported an ADLD family (ADLD-1-TO) without evidence of duplication or other mutation in LMNB1 despite linkage to the LMNB1 locus and lamin B1 overexpression. By custom array-CGH, we further investigated this family and report here that patients carry a large (∼660 kb) heterozygous deletion that begins 66 kb upstream of the LMNB1 promoter. Lamin B1 overexpression was confirmed in further ADLD-1-TO tissues and in a postmortem brain sample, where lamin B1 was increased in the frontal lobe. Through parallel studies, we investigated both loss of genetic material and chromosomal rearrangement as possible causes of LMNB1 overexpression, and found that ADLD-1-TO plausibly results from an enhancer adoption mechanism. The deletion eliminates a genome topological domain boundary, allowing normally forbidden interactions between at least three forebrain-directed enhancers and the LMNB1 promoter, in line with the observed mainly cerebral localization of lamin B1 overexpression and myelin degeneration. This second route to LMNB1 overexpression and ADLD is a new example of the relevance of regulatory landscape modifications in determining Mendelian phenotypes.

1 August 2014 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
EGEleonora Di Gregorio
Eleonora Di Gregorio
BBBarbara Borroni
Barbara Borroni
EGElisa Giorgio
Elisa Giorgio
DLDaniela Lacerenza
Daniela Lacerenza
MFMarta Ferrero
Marta Ferrero
ABAlfredo Brusco
Alfredo Brusco

21 December 2021 in Genes
Verified
Journal Article
Open access
PDF file
AMAlessandro Mussa
Alessandro Mussa
DCDiana Carli
Diana Carli
EGElisa Giorgio
Elisa Giorgio
AVANNA MARIA VILLAR
ANNA MARIA VILLAR
Simona CardaropoliSimona Cardaropoli
Simona Cardaropoli
GFGiovanni Battista Ferrero
Giovanni Battista Ferrero
The RAF1:p.Ser257Leu variant is associated with severe Noonan syndrome (NS), progressive hypertrophic cardiomyopathy (HCM), and pulmonary hypertension. Trametinib, a MEK-inhibitor approved for treatment of RAS/MAPK-mutated cancers, is an emerging treatment option for HCM in NS. We report a patient with NS and HCM, treated with Trametinib and documented by global RNA sequencing before and during treatment to define transcriptional effects of MEK-inhibition. A preterm infant with HCM carrying the RAF1:p.Ser257Leu variant, rapidly developed severe congestive heart failure (CHF) unresponsive to standard treatments. Trametinib was introduced (0.022 mg/kg/day) with prompt clinical improvement and subsequent amelioration of HCM at ultrasound. The appearance of pulmonary artery aneurysm and pulmonary hypertension contributed to a rapid worsening after ventriculoperitoneal shunt device placement for posthemorrhagic hydrocephalus: she deceased for untreatable CHF at 3 months of age. Autopsy showed severe obstructive HCM, pulmonary artery dilation, disarrayed pulmonary vascular anatomy consistent with pulmonary capillary hemangiomatosis. Transcriptome across treatment, highlighted robust transcriptional changes induced by MEK-inhibition. Our findings highlight a previously unappreciated connection between pulmonary vascular disease and the severe outcome already reported in patients with RAF1-associated NS. While MEK-inhibition appears a promising therapeutic option for HCM in RASopathies, it appears insufficient to revert pulmonary hypertension.

3 May 2013 in Human Mutation
Verified
Journal Article
Open access
PDF file
EGElisa Giorgio
Elisa Giorgio
HRHarshvardhan Rolyan
Harshvardhan Rolyan
LKLaura Kropp
Laura Kropp
ACAnish Baswanth Chakka
Anish Baswanth Chakka
SYSvetlana Yatsenko
Svetlana Yatsenko
QPQuasar Saleem Padiath
Quasar Saleem Padiath
Autosomal dominant leukodystrophy (ADLD) is an adult onset demyelinating disorder that is caused by duplications of the lamin B1 (LMNB1) gene. However, as only a few cases have been analyzed in detail, the mechanisms underlying LMNB1 duplications are unclear. We report the detailed molecular analysis of the largest collection of ADLD families studied, to date. We have identified the minimal duplicated region necessary for the disease, defined all the duplication junctions at the nucleotide level and identified the first inverted LMNB1 duplication. We have demonstrated that the duplications are not recurrent; patients with identical duplications share the same haplotype, likely inherited from a common founder and that the duplications originated from intrachromosomal events. The duplication junction sequences indicated that nonhomologous end joining or replication‐based mechanisms such fork stalling and template switching or microhomology‐mediated break induced repair are likely to be involved. LMNB1 expression was increased in patients’ fibroblasts both at mRNA and protein levels and the three LMNB1 alleles in ADLD patients show equal expression, suggesting that regulatory regions are maintained within the rearranged segment. These results have allowed us to elucidate duplication mechanisms and provide insights into allele‐specific LMNB1 expression levels.

31 October 2014 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
CMCecilia Mancini
Cecilia Mancini
SNStefano Nassani
Stefano Nassani
YGYiran Guo
Yiran Guo
YCYulan Chen
Yulan Chen
EGElisa Giorgio
Elisa Giorgio
ABAlfredo Brusco
Alfredo Brusco

30 January 2015 in Human Molecular Genetics
Verified
Journal Article
Open access
ABA. Bartoletti-Stella
A. Bartoletti-Stella
LGL. Gasparini
L. Gasparini
CGC. Giacomini
C. Giacomini
PCP. Corrado
P. Corrado
RTR. Terlizzi
R. Terlizzi
SCSabina Capellari
Sabina Capellari
Adult-onset autosomal dominant leukodystrophy (ADLD) is a slowly progressive neurological disorder characterized by autonomic dysfunction, followed by cerebellar and pyramidal features. ADLD is caused by duplication of the lamin B1 gene (LMNB1), which leads to its increased expression. The molecular pathways involved in the disease are still poorly understood. Hence, we analyzed global gene expression in fibroblasts and whole blood of LMNB1 duplication carriers and used Gene Set Enrichment Analysis to explore their gene signatures. We found that LMNB1 duplication is associated with dysregulation of genes involved in the immune system, neuronal and skeletal development. Genes with an altered transcriptional profile clustered in specific genomic regions. Among the dysregulated genes, we further studied the role of RAVER2, which we found to be overexpressed at mRNA and protein level. RAVER2 encodes a putative trans regulator of the splicing repressor polypyrimidine tract binding protein (PTB) and is likely implicated in alternative splicing regulation. Functional studies demonstrated an abnormal splicing pattern of several PTB-target genes and of the myelin protein gene PLP1, previously demonstrated to be involved in ADLD. Mutant mice with different lamin B1 expression levels confirmed that Raver2 expression is dependent on lamin B1 in neural tissue and determines an altered splicing pattern of PTB-target genes and Plp1. Overall our results demonstrate that deregulation of lamin B1 expression induces modified splicing of several genes, likely driven by raver-2 overexpression, and suggest that an alteration of mRNA processing could be a pathogenic mechanism in ADLD.